You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Ultra-sensitive Rapid Diagnostic Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis
SBC: NANOCOMPOSIX, INC. Topic: NIAIDProject SummaryAbstract Lymphatic filariasisLFcaused by the parasitic filarial worm Wuchereria bancroftiis a disfiguring and debilitating neglected tropical disease that affectsmillion people incountriesThrough the World Health Organization sWHOGlobal Program for the Elimination of Lymphatic FilariasisGPELFbillion drug regimens have been distributed via mass drug administrationMDAtomillion people ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a Neonatal Jaundice Treatment Accelerator by Circumferential Redirection of Unused Phototherapy Light onto the Infants Untreated Skin Surface
SBC: Arbor Grace Inc. Topic: NICHDPROJECT SUMMARY ABSTRACT Neonatal jaundice continues to be a significant global problem affectingof preterm andof term neonates while severe neonatal jaundice affects at leastneonates annuallyJaundice and jaundice related complications like Kernicterus Spectrum DisorderKDSare gaining recognition among the worldandapos s health policy leaders as an important area for further research and developmen ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction
SBC: Renova Therapeutics, Inc. Topic: NHLBIABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A microfluidic device for blood analysis in neonates
SBC: Sersense Inc Topic: NICHDABSTRACT Premature infants are frequently at risk of infectionjaundice and hypoglycemiaconditions monitored by analysis of blood for c reactive proteinCRPbilirubin and glucose respectivelyTypicallymL of blood is drawn each time an infant is tested with multiple blood draws happening over the course of daysGiven that total blood volume of in premature infants ismLup toof blood volume may be lost du ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques
SBC: Navidea Biopharmaceuticals, Inc. Topic: NHLBIMyocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma
SBC: Avenzoar Pharmaceuticals, Inc. Topic: 102ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A 3D Printed Resorbable Antimicrobial Envelope to Prevent Infection of Implanted Cardiac Devices
SBC: N8 MEDICAL INC Topic: NHLBIABSTRACT Infection is a serious and potentially fatal complication of surgery to deliver cardiovascular implantable electronic devicesCIEDsi epacemakers and implantable cardioverter defibrillatorsUntreated device related infection is associated with mortality rates as high asCurrentlyonly one antibiotic impregnated mesh has been FDA approved for placement in surgical incisions to reduce infections ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of OCT Imaging Adapter for Interstitial Tissue Imaging
SBC: WEST FACE MEDICAL DEVICES, INC. Topic: NIBIBDESCRIPTION provided by applicant This Phase I STTR Grant Proposal requests $ support for WestFace Medical Device to construct and test the WestFace Imaging Adaptor in conjunction with Ruikang K Wang PhD and his laboratory at the University of Washington Utilizing optical coherence tomography OCT the patented OCT Adaptor USPTO Pats provides r ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health